Navigation Links
EntreMed Receives Notice of NASDAQ Compliance
Date:10/15/2010

ROCKVILLE, Md., Oct. 15 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today announced that it has received a letter from the NASDAQ Stock Market indicating that it has regained compliance with the minimum $35 million Market Value of Listed Securities ("MVLS") requirement for continued listing on the NASDAQ Capital Market as set forth in NASDAQ Marketplace Rule 5550(b)(2).(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO)

On August 17, the Company received a Staff Determination Letter from NASDAQ stating that it was not in compliance with the rule because its MVLS failed to meet the required $35 million minimum for the last 30 consecutive business days.  At that time, the Company was granted 180 calendar days, or until February 14, 2011, to regain compliance with the rule.  

In order to regain compliance, the Company was required to maintain a $35 million MVLS for a minimum of 10 consecutive business days.  In its October 13, 2010 notification, NASDAQ provided written confirmation that EntreMed has regained compliance with the rule and that this matter is now closed.

About EntreMedEntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.  ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.  Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking StatementsThis release contains forward-looking
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... June 2, 2015  Psychemedics Corporation (NASDAQ: PMD ... twenty-five years, announced the addition of 2 new drugs ... growing abuse concerns, the addition of Oxymorphone was made ... added as an option to the Amphetamine panel. ... stated:  "Sadly, more and more prescription drugs are being ...
(Date:6/2/2015)... , June 02, 2015 Research ... addition of the "Motion Simulation Market by ... DOF, Three DOF, and Six DOF), Application (Automotive, ... and Region - Forecast to 2020 " ... simulation is considered to have matured enough for ...
(Date:6/2/2015)... 2, 2015  Lannett Company, Inc. (NYSE: ... the acquisition of privately held, Silarx Pharmaceuticals, Inc. ... a manufacturer and marketer of liquid generic pharmaceutical ... to acquire Silarx on May 15, 2015.   ... evaluating a number of potential acquisitions, we are ...
Breaking Medicine Technology:Psychemedics Announces Addition Of FDA Cleared Drugs 2Psychemedics Announces Addition Of FDA Cleared Drugs 3Global Motion Simulation Market 2015-2020 - Type, Degree of Freedom, Application, and Regional Analysis 2Lannett Completes Acquisition Of Silarx Pharmaceuticals, Inc. 2
... NEW YORK, Oct. 19 Reportlinker.com announces ... available in its catalogue: ... Pharmaceutical Market in China: Growth strategies, performance ... http://www.reportlinker.com/p0315841/The-Top-10-Companies-in-the-Hospital-Pharmaceutical-Market-in-China-Growth-strategies-performance-and-SWOT-analyses.html China is currently ...
... Reportlinker.com announces that a new market ... Triple Analysis: Apoptosis, Angiogenesis ... http://www.reportlinker.com/p0284949/Triple-Analysis-Apoptosis-Angiogenesis-and-Protein-Kinase-Inhibitors.html This triple ... by mechanism/target/effect of Apoptosis, Angiogenesis and Protein ...
Cached Medicine Technology:Reportlinker Adds The Top 10 Companies in the Hospital Pharmaceutical Market in China: Growth strategies, performance and SWOT analyses 2Reportlinker Adds The Top 10 Companies in the Hospital Pharmaceutical Market in China: Growth strategies, performance and SWOT analyses 3Reportlinker Adds The Top 10 Companies in the Hospital Pharmaceutical Market in China: Growth strategies, performance and SWOT analyses 4Reportlinker Adds The Top 10 Companies in the Hospital Pharmaceutical Market in China: Growth strategies, performance and SWOT analyses 5Reportlinker Adds The Top 10 Companies in the Hospital Pharmaceutical Market in China: Growth strategies, performance and SWOT analyses 6Reportlinker Adds The Top 10 Companies in the Hospital Pharmaceutical Market in China: Growth strategies, performance and SWOT analyses 7Reportlinker Adds The Top 10 Companies in the Hospital Pharmaceutical Market in China: Growth strategies, performance and SWOT analyses 8Reportlinker Adds The Top 10 Companies in the Hospital Pharmaceutical Market in China: Growth strategies, performance and SWOT analyses 9Reportlinker Adds Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors 2Reportlinker Adds Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors 3Reportlinker Adds Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors 4Reportlinker Adds Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors 5
(Date:6/2/2015)... 2015 The nation’s first trial ... http://www.consumerinjurylawyers.com/wright-profemur-hip-replacement ) is now underway in California Superior ... opening statements were presented on May 28th, with ... the Profemur hip replacement made the device brittle ... just three years after it had been implanted ...
(Date:6/2/2015)... “ Radaris ” was featured on NewsWatch as ... the latest and coolest applications on the market for iOS, ... technology expert, conducted the app review and shared with viewers ... a person. , According to Psychology Today, humans are a ... explain that curiosity is a part of human development. People ...
(Date:6/2/2015)... Milton Hershey School® graduate Vincent Klomps ’10 ... of the Physician Assistant Program’s entering class of 2015 ... with a white coat, which symbolizes his entrance into ... of Vincent’s accomplishments both at MHS and postgraduation,” said ... of how a top-notch education can lead to achievement ...
(Date:6/2/2015)... Erbelli’s Gourmet Pizzeria, Italian Bistro & Pub ... gourmet pizzas and calzones, fresh wraps, submarine sandwiches, and ... the recipes are not—they have been satisfying the taste ... the site is the menu, which is broken up ... the items. You can order directly from the website ...
(Date:6/2/2015)... 02, 2015 IMPAK Corporation, a ... has announced the availability of “child-resistant” pouches and ... by children, especially curious toddlers. The Child Resistant ... tested to CFR 1700.20 protocols. The announcement was ... Looks Like Candy, “With the proliferation of consumer ...
Breaking Medicine News(10 mins):Health News:First of More Than 1,200 Wright Hip Lawsuits Goes to Trial in California Superior Court 2Health News:First of More Than 1,200 Wright Hip Lawsuits Goes to Trial in California Superior Court 3Health News:A Comprehensive People Search Application Was Featured on NewsWatch Television 2Health News:Erbelli’s of Bradenton Launches New Mobile-Friendly Website 2Health News:IMPAK Introduces Child Resistant Zip Pouches & Bags 2
... , Republican Congressman Slated to ... h and Insurance Campaign Contributions , , ... conflict of interest questions about Rep. Charles Boustany (R-La.) and the ... Barack Obama,s speech to a joint session of Congress on health ...
... , , KEYSTONE TREATMENT AND OUTREACH ... SIMILAR EVENTS TO FOLLOW AT CANTON AT 1 PM: , KEYSTONE ... Media welcome at both locations , , SIOUX FALLS ... Falls, S.D. will be the 2009 national headquarters at 11 AM Wednesday, September ...
... , , , ... LLC, a leading infant formula company, has introduced Bright Beginnings(R) ... Beginnings(R) NeoCare(TM) is a milk-based infant formula intended to meet ... hospital discharge. , , Clinical evidence suggests ...
... produces mild infection, but severe reactions can result , WEDNESDAY, ... has been infected with the West Nile virus, whether they ... since the virus first appeared in North America in 1999, ... journal Emerging Infectious Diseases . , Several West Nile ...
... Industries Ltd. (NYSE: NBR ) invites you to join Eugene M. Isenberg, Chairman and ... third quarter 2009. Nabors will release earnings after the market closes on October 20, 2009. , ... October 21, 2009, Time: ... a.m. ET), Dial-in-number:, Domestic: ...
... , , LEWISTON, Maine and ... presenting sponsor of The Dempsey Challenge: A Journey for Hope, a cycling ... event supports The Patrick Dempsey Center for Cancer Hope & Healing at ... provides an opportunity to expand Amgen,s Breakaway from Cancer ((R)) ...
Cached Medicine News:Health News:Rep. Boustany Hauled in $1.25 Million From Health and Insurance Industry 2Health News:Wed., Sept. 16, 11 AM News Conference: Sioux Falls' Keystone Treatment Center Is National HQ to Lead 100 Locations Nationwide in Balloon Liftoff Celebrating Recovery Against New Wave of Drug Abuse; Former U.S. Drug Czar/4-Star Gen. Barry McCaffrey, Lieute 2Health News:Bright Beginnings(R) NeoCare(TM) Value-Priced Weight Gain Infant Formula Now Available Online at www.pbmstore.com 2Health News:Study Shows 1% of Americans Have Been Infected With West Nile 2Health News:Study Shows 1% of Americans Have Been Infected With West Nile 3Health News:Amgen Named Presenting Sponsor of The Dempsey Challenge: A Journey For Hope 2Health News:Amgen Named Presenting Sponsor of The Dempsey Challenge: A Journey For Hope 3Health News:Amgen Named Presenting Sponsor of The Dempsey Challenge: A Journey For Hope 4
... Since 1991 Intersurgical Incorporated ... filters, heat and moisture ... therapy products, hand-held nebulizers ... of accessories and connectors ...
... The Ulti-Mist™ HME product line has ... from pediatrics to adults and from intubated ... offer superior humidification for both anesthesia and ... and HME/Filters provide maximum protection for patients ...
Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
Medicine Products: